Humana (HUM) Jumped, But What Is The Market Seeing Now?

Humana (HUM) just reported third quarter 2026 results, with revenue at US$41.2b and net income at US$162m, and raised its full year earnings outlook after topping profit expectations.

Humana’s latest earnings beat and guidance raise have arrived after a strong run in the shares, with the stock up 64.0% year to date and a 1-year total shareholder return of 74.34% at a US$433.74 share price.

Scan how Humana’s post earnings surge compares with other insurers by zeroing in on 29 resilient stocks with low risk scores that pair resilient balance sheets with steadier return profiles.

After a 64.0% year-to-date jump and a higher earnings outlook, Humana now presents a timing decision. Is the current price fair compensation, or is waiting for a cheaper entry the better trade-off before evaluating the valuation?

Most Popular Narrative: 7% Undervalued

Humana’s most followed valuation storyline pegs fair value at $465.13 using a 7.24% discount rate, compared with the latest $433.74 close. This puts the recent post earnings surge in context for anyone weighing upside against execution risk.

The main thing that has to go right is that Humana delivers on its multiyear Medicare Advantage margin and cost-transformation program, including disciplined plan pruning, operating cost ratio reductions, and effective value-based partnerships, while managing regulatory and compliance risks.

The current narrative that Humana is fairly valued and bullish implies the share price already reflects meaningful progress on margin restoration, operating cost efficiencies, and balance sheet optimization with limited room for disappointment if these plans slip.

See why 61 investors see Humana as 7% undervalued.

Result: Fair Value of $465.13 (UNDERVALUED)

Still, Humana’s Medicare Advantage exits for about 600,000 members and ongoing scrutiny of coding and Stars rules could easily shift this valuation narrative.

Find out about the key risks to this Humana narrative.

Next Steps

Mixed signals around Humana’s valuation and execution plans make this a moment to move quickly, review the underlying data, and form your own stance, then weigh those signals against the 2 key rewards and 1 important warning sign.

Looking for more Humana-like investment ideas?

If Humana has sharpened your focus, use this momentum to widen your watchlist and pressure test your thesis against other well screened opportunities.

• Pinpoint resilient balance sheet performers by scanning the list of solid balance sheet and fundamentals (24 results) that combine financial strength with cleaner fundamentals.
• Hunt for mispriced opportunities by reviewing the 19 high quality undiscovered gems that pair quality metrics with lighter market attention.
• Build a watchlist of potential income pillars by assessing the 8 dividend fortresses that screen for higher yields with sturdier profiles.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com